A new drug combination for rheumatoid arthritis treats the disease just as well as other intensive treatment strategies but with less medication and fewer side effects at a significantly lower cost.
Rheumatoid arthritis (RA) is a chronic auto-immune disease that causes pain and stiffness in the joints, fatigue, bone damage and, eventually, loss of mobility. RA afflicts around 1% of people in the western world; in Belgium, 80,000 to 100,000 people currently live with the disease.
Because there is no known cure for RA, physicians focus treatment on suppressing disease activity. Therapies have improved in recent years, and clinical studies show that intensive treatment of early RA can prevent joint damage and improve patients’ quality of life.
In the two-year study, called ‘CareRA’ (Care in early RA), researchers and clinicians in the rheumatology unit at University Hospitals Leuven examined various therapies for early RA. Their goal: to find the optimal combination and dosage of three commonly prescribed antirheumatic drugs (methotrexate, sulfasalazine and leflunomide) in combination with glucocorticoids (a class of steroid hormones).
The researchers divided 290 early RA patients into three treatment groups. Each group received a different combination therapy: ‘COBRA Classic’ (methotrexate, sulfasalazine and a high first dose of glucocorticoids), ‘COBRA Slim’ (methotrexate and a moderate dose of glucocorticoids) or ‘COBRA Avant-Garde’ (methotrexate, leflunomide and a moderate dose of glucocorticoids).
Fewer side effects
All three strategies showed a similarly high efficacy: disease remission was achieved in 7 in 10 patients after 16 weeks of treatment. But results for the strategies varied significantly when it came to side effects.
The new COBRA Slim strategy, which calls for the least amount of medication, had half as many side effects as the two other strategies – and was just as effective. The strategy would also be easier to implement in daily practice because it is less complicated.
A broader use of this strategy would lead to higher remission rates in the global early RA population and would probably reduce the need for expensive second-line antirheumatic treatment, say the researchers.
The Latest on: Rheumatoid arthritis
via Google News
The Latest on: Rheumatoid arthritis
- Coronavirus: Hydroxychloroquine sought for goldfish with arthritison May 13, 2020 at 1:25 am
The pace has almost returned to the everyday at HealthWarehouse, so Jenny Trenkamp and Ross Goetz can reflect now on their roles in ...
- Rheumatoid Arthritis Triple Therapy Little Used in U.S.on May 8, 2020 at 10:04 am
Outcomes favored methotrexate plus a TNF inhibitor versus methotrexate plus hydroxychloroquine and sulfasalazine ...
- Coronavirus Treatment: Arthritis Drug Appears Promising With 90% Survival Rate And Reduced Respiratory Symptomson May 8, 2020 at 6:10 am
Rheumatoid Arthritis drug anakinra has been reported to be promising in treating acute respiratory distress syndrome and hyper-inflammation in COVID-19 patients reported a new stu ...
- Rheumatoid Arthritis Treatment Market 2020-2026 Global Review and Outlook | Sanofi SA, Pfizer Inc., Roche Holding AGon May 8, 2020 at 12:44 am
Global Rheumatoid Arthritis Treatment Market, delivering a must-read report for industry stakeholders wanting to understand ...
- Arthritis Drug Shows Promise Treating Lung Inflammation That Is Leading Cause of Coronavirus-Related Deathson May 7, 2020 at 9:10 pm
The arthritis drug anakinra is being studied as a potential treatment for reducing acute respiratory distress syndrome in COVID-19 patients.
- In Small Study, Rheumatoid Arthritis Drug Appears to Help COVID-19 Patientson May 7, 2020 at 4:57 pm
In the scramble to find medicines that beat back COVID-19, researchers from Italy report encouraging results from a small study on a rheumatoid arthritis drug already in use. The drug, anakinra, may ...
- Arthritis drug shows promise against respiratory distress caused by COVID-19on May 7, 2020 at 4:21 pm
Anakinra, a drug developed to treat rheumatoid arthritis might help patients who have developed acute respiratory distress syndrome caused by COVID-19, a small study published by The Lancet ...
- Arthritis Drug Seen Helping Covid-19 Patients in Small Studyon May 7, 2020 at 3:30 pm
A drug for rheumatoid arthritis appeared to help improve lung function in hospitalized Covid-19 patients, a positive sign for treating those with severe inflammation in their organs.
- Red light could be used to precisely target rheumatoid arthritis drugson May 4, 2020 at 7:02 am
People with rheumatoid arthritis often take medicines that can have damaging side-effects, but a system that uses red light to deliver drugs exactly where they are needed could help ...
- Teva Launches Truxima Injection In U.S. To Treat Rheumatoid Arthritison May 4, 2020 at 5:50 am
(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) and Celltrion Healthcare have launched Truxima Injection in the United States for the treatment of Rheumatoid Arthritis. Truxima is also now ...
via Bing News